New Way to Target B-Cell Lymphomas 
Cancer Network
By Anna Azvolinsky, PhD | May 18, 2012 Researchers at the University of Pennsylvania have identified a protein that could be targeted to turn off B-cell lymphomas. The protein, CD19, was found to be a major regulator of B-cell neoplastic growth driven ...

 

Diffuse Large B-Cell Lymphoma: Current Treatment Approaches 
Cancer Network
ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoid malignancy. While a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all ...

and more » 

Protein May Represent a Switch to Turn Off B cell Lymphoma 
MarketWatch (press release)
Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma. B cell lymphomas ...

and more » 

Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial ... 
MarketWatch (press release)
The oral presentation, entitled "SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma", will describe the effectiveness of SNS01-T in B-cell cancers, which is designed ...

and more » 

EU Approves Pixantrone for Non-Hodgkin's B-Cell Lymphomas 
Medscape
... Pixantrone (Pixuvri, Cell Therapeutics) has received conditional marketing authorization from the European Commission as monotherapy for the treatment of adults with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas (NHL).
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat ... MarketWatch (press release)
EC Conditionally Approves Cell Therapeutics' Pixantrone for Non-Hodgkin Lymphoma Genetic Engineering News
Cell Therapeutics gets approval to market cancer drug Pixuvri in Europe Bizjournals.com
NASDAQ  -PharmaLive (press release) (subscription) 
all 26 news articles » 

Protein may represent a switch to turn off B cell lymphoma 
Medical Xpress
Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma. B cell lymphomas ...

and more » 

Cell Therapeutics' Lymphoma Drug Wins Conditional EU Approval 
Wall Street Journal
Cell Therapeutics Inc. (CTIC) won conditional authorization to market its treatment for non-Hodgkin B-cell lymphomas in the European Union, a key regulatory win for the drug maker. Shares were halted at $1.04 Thursday ahead of the news.
Pixuvri Approved For Adult Patients With Refractory Aggressive Non-Hodgkin B ... Science 2.0
Drug Approval! Oh, Wait, We Knew That Already. DailyFinance
Cell Therapeutics' Pixuvri receives European Union approval Pharmaceutical Business Review
24/7 Wall St. 
all 10 news articles » 

Biovest Announces BiovaxID(R) ASCO Abstract Available On-line; NCI to Present ... 
MarketWatch (press release)
Biovest's lead drug product is BiovaxID(R), an autologous active immunotherapy (personalized cancer vaccine) for the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma, an incurable form of blood cancer. Over the past decade, ...

and more » 

Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination ... 
MarketWatch (press release)
ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients ...
Spectrum begins Phase II NHL study with Zevalin Pharmaceutical Business Review

all 5 news articles » 

Mirna Reports on Role of miR-34a in B Cell Lymphoma, Expands Planned Phase I ... 
GenomeWeb
According to the paper, which appeared in Leukemia, the investigators showed that diffuse B cell lymphoma can transform from an indolent to an aggressive state when miR-34 expression is lost. ?By giving miR-34 back into tumors, you can control tumor ...